Target
tyrosine kinase receptor
7 abstracts
Abstract
A single-arm, phase II trial assessing the combination of AK105 and anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer.Org: The First Affiliated Hospital of Zhengzhou University, Zhengzhou Gensciences, China National Biotec Group,
Abstract
Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinical trial (TQB2450-II-08).Org: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Department of Gynecology Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Gynecologic Radiation Department, Zhejiang Cancer Hospital, Beijing Chao-Yang Hospital,Capital Medical University, Oncology Department, Beijing Luhe Hospital, Capital Medical University,
Abstract
A phase II trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor–resistant, metastatic breast cancer.Org: The Third Hospital of Nanchang, Nanchang People's Hospital,
Abstract
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.Org: Chengdu Shang Jin Nan Fu Hospital,
Abstract
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology Co. Ltd,
Abstract
Efficacy of subsequent immunotherapy-tyrosine kinase inhibitor combinations after TKI monotherapy failure in patients with intermediate/poor risk metastatic clear cell renal cell carcinoma: A real-world retrospective study.Org: Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Pek, Beijing, China, Cancer Hospital of HuanXing Chaoyang District Beijing, Beijing, People's Republic of China., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
Camrelizumab combined with tyrosine kinase inhibitors in the treatment of patients with advanced renal cell carcinoma: A single-center prospective exploratory study.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China,